Rigel Pharmaceuticals
RIGL
Market Cap$338.32M
Close$
$-10.27
154.7% downside
Current Fair Value
154.7% downsideOvervalued by 154.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $338.32 Million |
|---|---|
| Enterprise Value | $358.97 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.99 |
| Beta | 1.29 |
| Outstanding Shares | 17,808,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 9.07 |
|---|---|
| PEG | -3.8 |
| Price to Sales | 1.71 |
| Price to Book Ratio | 18.76 |
| Enterprise Value to Revenue | 1.77 |
| Enterprise Value to EBIT | 7.97 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 3.57 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez